The DPP8 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma cell line NCI-H1975. This polyclonal pool carries targeted disruption of the DPP8 gene, generating a loss-of-function model for studying DPP8-dependent biological processes. The polyclonal format provides a heterogeneous knockout population suitable for investigating gene function without the clonal artifacts that can arise from single-cell-derived lines.
NCI-H1975 is an extensively characterized epithelial cell line derived from a human non-small cell lung cancer (NSCLC). It harbors activating mutations in the epidermal growth factor receptor (EGFR), specifically the L858R and T790M variants, which contribute to its oncogenic properties and relevance as a model for EGFR-mutant lung adenocarcinoma. This cell line is widely employed in NSCLC research, including studies of drug resistance, tumor progression, and signal transduction.
DPP8 encodes a dipeptidyl peptidase serine protease that cleaves N-terminal dipeptides from bioactive peptides, influencing immune regulation, cell proliferation, and apoptosis. DPP8 is activated by upstream signals including TNF-?? and IFN-?? and interacts with key inflammasome components. It forms complexes with DPP9 and directly binds NLRP1, acting as a negative regulator of the NLRP1 inflammasome. DPP8 disruption relieves this inhibition, leading to NLRP1-dependent recruitment of ASC and activation of caspase-1. Active caspase-1 then processes pro-IL-1?? and pro-IL-18 into mature cytokines, promoting inflammatory responses and potentially inducing pyroptosis. DPP8 also modulates CXCL10 expression and intersects with Wnt signaling.
In the NCI-H1975 background, DPP8 knockout critically alters the tumor inflammatory microenvironment. Loss of DPP8 function activates NLRP1 inflammasome signaling, driving caspase-1-mediated maturation of IL-1?? and IL-18 and triggering pyroptotic cell death. This can reshape immune cell recruitment and tumor-immune interactions, making the model valuable for investigating how DPP8-dependent inflammasome regulation influences NSCLC progression, drug response, and immune evasion strategies. The EGFR-mutant status further provides a clinically relevant context for examining cross-talk between oncogenic signaling and innate immune pathways.
This polyclonal DPP8 knockout cell population supports a broad range of experimental applications, including mechanistic studies of NLRP1 inflammasome regulation, investigation of DPP8 function in the NSCLC tumor microenvironment, and drug target validation for inflammatory diseases. Researchers can employ Western blotting to assess DPP8, caspase-1, and IL-1?? levels; ELISA to quantify secreted IL-1?? and IL-18; RT-qPCR for pro-inflammatory cytokine transcripts; LDH release assays to monitor pyroptosis; flow cytometry for Annexin V/PI staining and active caspase-1 detection; co-immunoprecipitation to examine DPP8-NLRP1 interactions; and drug sensitivity assays utilizing DPP8/9 inhibitors. For additional product details, technical support, or ordering information, please contact Ascent Research.
